viewZelira Therapeutics Ltd

Zelira Therapeutics MD shows faith in medical cannabis strategy with placement participation

Dr Richard Hopkins purchased 1 million shares in the heavily oversubscribed A$8.75 million placement and now holds 1.7 million shares.

Zelira Therapeutics Ltd - Zelira Therapeutics MD shows faith in medical cannabis strategy with placement participation
The company is well-funded to advance its unique ‘Launch, Learn and Develop’ model

Zelira Therapeutics Ltd’s (ASX:ZLD) (OTCMKTS:ZLDAF) managing director Dr Richard Hopkins has shown his faith in the company’s therapeutic medicinal cannabis strategy by participating in a placement that raised A$8.75 million.

On August 11, 2020, Hopkins acquired 1 million shares at A$0.05 per share after his participation in the placement was approved by shareholders on July 21, 2020.

The purchase has taken the MD’s overall holding of fully paid ordinary shares held in an indirect interest to 1.7 million.

Strongly oversubscribed

Zelira’s placement of 175 million shares at A$0.05 per share was strongly oversubscribed by new and existing investors in Australian and the United States.

Managed by Morgan’s Corporate Ltd, the placement received firm bids exceeding twice the intended amount and is set to increase the company’s cash position to around A$10.35 million, before costs.


The company is well-funded to leverage its unique ‘Launch, Learn and Develop’ model to launch products, generate revenues and progress development of clinically validated medicines.

Zelira owns a portfolio of proprietary revenue-generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020.

The company is focused on developing branded cannabis products for the treatment of a variety of medical conditions.

Quick facts: Zelira Therapeutics Ltd


Price: 0.04 AUD

Market Cap: $47.61 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


Zelira Therapeutics and Levin Health talk upcoming chronic pain clinical trial

Zelira Therapeutics Ltd's (ASX:ZLD) (OTCMKTS:ZLDAF) Dr Oludare Odumosu and Levin Health Limited's Mark Brayshaw discuss plans for its upcoming chronic pain clinical trial. Levin will use Zelira's ZTL-106 formulation for testing on retired athletes in a chronic pain treatment study at La Trobe...

on 7/6/21

2 min read